Abstract
Atherosclerosis is a pathologic process affecting blood vessels, which leads to the development of cardiovascular disease. The immune system is involved in atherogenesis and in the pathogenesis of atherosclerosis. Several autoimmune rheumatic conditions, including rheumatoid arthritis, systemic lupus erythematosus and antiphospholipid syndrome, are characterized by enhanced atherosclerosis and consequently higher cardiovascular morbidity and mortality rates. Enhanced atherosclerosis, in these diseases, can manifest as overt cardiovascular diseases, but could be detected at an earlier stage by identification of abnormal endothelial function and arterial intima–media thickening. Both classical and nonclassical risk factors are presumed to contribute to atherosclerosis progression in rheumatic diseases. As atherosclerosis can be considered to be an immune-mediated process, several experimental strategies exist for its immunomodulation, including induction of immune tolerance. In this article, we briefly review the contribution of autoimmune elements, such as autoreactive lymphocytes and autoantibodies to atherosclerosis and discuss the nature of atherosclerosis in autoimmune rheumatic diseases.
Key Points
-
Autoimmune rheumatic diseases are characterized by enhanced atherosclerosis, which leads to cardiovascular disease
-
Some forms of atherosclerosis can be detected at the preclinical stage
-
Both cellular and humoral components of the immune system are involved in the pathogenesis of atherosclerosis
-
Classical and nonclassical risk factors for atherosclerosis are associated with accelerated atherosclerosis in autoimmune rheumatic diseases
-
Atherosclerosis can be immunomodulated in experimental models in various ways, which include induction of immune tolerance
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Shoenfeld Y et al. (2001) Atherosclerosis as an infectious, inflammatory and autoimmune disease. Trends Immunol 22: 293–295
Hansson GK (2005) Inflammation, atherosclerosis and coronary artery disease. N Engl J Med 352: 49–59
Hallenbeck JM et al. (2005) Immunology of ischemic vascular disease: plaque to attack. Trends Immunol 26: 550–556
Danesh J et al. (2004) C-reactive proteins and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350: 1387–1397
Emeson EE et al. (1996) Inhibition of atherosclerosis in CD4 T-cell-depleted and nude (nu/nu) C57BL/6 hyperlipidemic mice. Am J Pathol 149: 675–685
Zhou X et al. (2000) Transfer of CD4+ T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 102: 2919–2922
George J et al. (2000) Adoptive transfer of beta-2-glycoprotein-I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice. Circulation 102: 1822–1827
Laurat E et al. (2001) In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 104: 197–202
Maggi E et al. (1994) LDL oxidation in patients with severe carotid atherosclerosis: a study of in vitro and in vivo oxidation markers. Arterioscler Thromb 14: 1892–1899
Lehtimaki T et al. (1999) Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol 19: 23–27
Salonen JT et al. (1992) Autoantibodies against oxidized LDL and progression of carotid atherosclerosis. Lancet 339: 883–887
Sherer Y et al. (2001) Coronary artery disease but not coronary calcification is associated with elevated levels of cardiolipin, beta-2-glycoprotein-I, and oxidized LDL antibodies. Cardiology 95: 20–24
George J et al. (1998) Hyperimmunization of apo-E mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 138: 147–152
Palinski W et al. (1995) Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci 92: 821–825
Chang MK et al. (2004) Apoptotic cells with oxidation-specific epitopes are immunogenic and pro-inflammatory. J Exp Med 200: 1359–1370
Shoenfeld Y et al. (2004) Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective? Circulation 110: 2552–2558
Xu Q et al. (1993) Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet 341: 255–259
Xu Q et al. (1992) Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler Thromb Vasc Biol 12: 789–799
George J et al. (1999) Enhanced fatty streak formation in C57BL/6J mice by immunization with heat shock protein-65. Arterioscler Thromb Vasc Biol 19: 505–510
George J et al. (2001) Cellular and humoral immune responses to heat shock protein both involved in promoting fatty-streak formation in LDL-deficient mice. J Am Coll Cardiol 38: 900–905
Vaarala O et al. (1995) Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 91: 23–27
Sherer Y et al. (2000) Coronary calcium and anti-cardiolipin antibody are elevated in patients with typical chest pain. Am J Cardiol 86: 1306–1311
George J et al. (1999) Immunolocalization of β2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 99: 2227–2230
Hasunuma Y et al. (1997) Involvement of β2-glycoprotein-I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 107: 569–573
George J et al. (1997) Atherosclerosis in LDL-receptor knockout mice is accelerated by immunization with anticardiolipin antibodies. Lupus 6: 723–729
George J et al. (1998) Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with beta2-glycoprotein I. Circulation 98: 1108–1115
Shoenfeld Y et al. (2005) Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112: 3337–3347
Petri M et al. (1992) Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 93: 513–519
Rosner S et al. (1982) A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death. Arthritis Rheum 25: 612–617
Petri M et al. (1992) Coronary artery disease risk factors in the Johns Hopkins lupus cohort: prevalence, recognition by patients and preventive practice. Medicine 71: 291–302
Svenungsson E et al. (2001) Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104: 1887–1893
Roman MJ et al. (2003) Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349: 2399–2406
Doria A et al. (2003) Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 62: 1071–1077
Ames PR et al. (2002) Anticardiolipin antibody titre and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus 11: 208–214
Vlachoyiannopoulus PG et al. (2003) Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study. Rheumatology 42: 645–651
Medina G et al. (2003) Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome. Ann Rheum Dis 62: 607–610
Ames PR et al. (2005) Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis 64: 315–317
del Rincon I et al. (2001) High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44: 2737–2745
Solomon DH et al. (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107: 1303–1307
Kaplan JM and McCune WJ (2003) New evidence for vascular disease in patients with early rheumatoid arthritis. Lancet 361: 1068–1069
Maradit-Kremers H et al. (2005) Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52: 722–732
del Rincon I et al. (2003) Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 48: 1833–1840
Gerli R et al. (2004) CD4+CD28− T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 109: 2744–2748
Zal B et al. (2004) Heat-shock protein 60-reactive CD4+CD28null T cells in patients with acute coronary syndrome. Circulation 109: 1230–1235
Swanberg M et al. (2005) MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nat Genet 37: 486–494
Maron R et al. (2002) Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation 106: 1708–1715
Harats D et al. (2002) Oral tolerance with heat shock protein 65 attenuates Mycobacterium tuberculosis-induced and high-fat-diet-driven atherosclerotic lesions. J Am Coll Cardiol 40: 1333–1338
George J et al. (2004) Suppression of early atherosclerosis in LDL-receptor deficient mice by oral tolerance with beta 2-glycoprotein I. Cardiovasc Res 62: 603–609
Sherer Y et al. (1999) Immunomodulation of various autoimmune diseases by intravenous immunoglobulin. Drugs Today 35: 513–518
Nicoletti A et al. (1998) Immunoglobin treatment reduces atherosclerosis in ApoE knockout mice. J Clin Invest 102: 910–918
Sherer Y and Shoenfeld Y (2002) Immunomodulation for treatment and prevention of atherosclerosis. Autoimmun Rev 1: 21–27
Puttini P et al. (2005) TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma. Autoimmun Rev 4: 153–161
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Sherer, Y., Shoenfeld, Y. Mechanisms of Disease: atherosclerosis in autoimmune diseases. Nat Rev Rheumatol 2, 99–106 (2006). https://doi.org/10.1038/ncprheum0092
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0092
This article is cited by
-
Immunologic burden links periodontitis to acute coronary syndrome: levels of CD4 + and CD8 + T cells in gingival granulation tissue
Clinical Oral Investigations (2024)
-
Stroke risk in rheumatoid arthritis patients: exploring connections and implications for patient care
Clinical and Experimental Medicine (2024)
-
Endothelial Progenitor Cells in Autoimmune Disorders
Stem Cell Reviews and Reports (2023)
-
The potential role of Colchicine in preventing coronary vascular disease in childhood‐onset lupus: a new view on an old drug
Pediatric Rheumatology (2021)
-
Cardiovascular magnetic resonance in women with cardiovascular disease: position statement from the Society for Cardiovascular Magnetic Resonance (SCMR)
Journal of Cardiovascular Magnetic Resonance (2021)